Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study.
Fiche du document
- doi: 10.1016/j.athplu.2021.08.003
- issn: 2667-0895
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.athplu.2021.08.003
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36644508
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2667-0895
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6546628A58945
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Therapy Council of Europe countriesCiter ce document
K.K. Ray et al., « Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study. », Serveur académique Lausannois, ID : 10.1016/j.athplu.2021.08.003
Métriques
Partage / Export
Résumé
Clinical practice before 2019 suggests a substantial proportion of high and very high CV risk patients taking lipid-lowering therapy (LLT) would not achieve the new LDL-C goals recommended in the 2019 ESC/EAS guidelines (